drugset / Trial / NCT04477343
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1
Active not recruiting
20 enrolled
University of Rochester
Bristol-Myers Squibb · collabSyntrix Biosystems, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
Timeline
- Start
- 2020-11-23
- Primary completion
- 2026-05-06
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | SX-682 | Small molecule | 25 mg | Oral |
| Subject | SX-682 | Small molecule | 50 mg | Oral |
| Subject | SX-682 | Small molecule | 100 mg | Oral |
| Subject | SX-682 | Small molecule | 200 mg | Oral |
| Subject | SX-682 | Small molecule | 400 mg | Oral |